23 Followers on Owler

Recordati engages in the research, development, manufacture, marketing and sale of pharmaceutical drugs for the treatment of rare diseases...

Read more

Recordati engages in the research, development, manufacture, marketing and sale of pharmaceutical drugs for the treatment of rare diseases...

Read more
Recordati CEO: Robert Koremans

CEO

Robert Koremans

CEO Approval Rating

- -/100

Annual Revenue
$1.9B
Employees
4,362
Funding
$0
Acquisitions
10

News

Nov 12, 2022
Seeking Alpha
Recordati: Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2022 Earnings Call Transcript
Aug 31, 2022
Business Wire
Press Release: Recordati : Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa (Osilodrostat) in Patients With Cushing's Disease in the European Journal of Endocrinology
Jul 28, 2022
MarketScreener
Recordati: RECORDATI FIRST HALF 2022 RESULTS: REVENUE +15.8%, EBITDA +11.5%, ADJUSTED NET INCOME +7.1%. 2022 TARGETS CONFIRMED, WITH REVENUE EXPECTED AT TOP END OF THE GUIDANCE RANGE
May 10, 2022
MarketScreener
Recordati: Recordati confirms 2022 targets despite Ukraine conflict
Apr 29, 2022
MarketScreener
Recordati: RECORDATI: THE SHAREHOLDERS' MEETING APPROVES THE 2021 FINANCIAL STATEMENTS. DIVIDEND OF 1.10 PER SHARE (+4.8% vs 2020). THE NEW BOARD OF DIRECTORS HAS BEEN APPOINTED
Apr 08, 2022
MarketScreener
Recordati: Recordati : Direct proxy form to the Designated Representative pursuant to art. 135-undecies of Leg. Decree 58/98
Apr 01, 2022
MarketScreener
Recordati: Recordati : Directors' Report on item 4 on the agenda - Authorization to the purchase and disposal of treasury stock
Apr 01, 2022
MarketScreener
Recordati: Recordati : Report of the Board of Statutory Auditors to the Shareholders' Meeting
Apr 01, 2022
MarketScreener
Recordati: Recordati : Financial Statements of Recordati S.p.A. at 31 December 2021 and related Report of the Auditing Firm
Mar 18, 2022
MarketScreener
Recordati: RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS' 29.04.2022)

Recordati Competitors

1
2
3
4
5
6
7
8
9
10

Recordati Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$1.9B

Recordati's revenue is the ranked 28th among it's top 10 competitors. The top 10 competitors average 27.8B. Over the last four quarters, Recordati's revenue has decreased by 17.3%. Specifically, in Q3 2021's revenue was $448.6M; in Q2 2021, it was $459.5M; in Q1 2021, it was $451.7M; in Q4 2020, Recordati's revenue was $542.2M.

Recordati News

Recordati Press Releases

Recordati Videos

Recordati Headquarters

Via Matteo Civitali 1

Milan, Lombardy20148

007-482-10150

Driving Directions »

Recordati Summary

ABOUT

Overview

Recordati engages in the research, development, manufacture, marketing and sale of pharmaceutical drugs for the treatment of rare diseases. Recordati was founded in 1926. Recordati's headquarters is located in Milan, Lombardy, IT 20148. Recordati has ...

Funding

Funding data cannot be found related to Recordati

Investments

Recent investment data cannot be found related to Recordati

Frequently Asked Questions about Recordati

  1. When was Recordati founded?

    Recordati was founded in 1926
  2. Who is Recordati's CEO?

    Recordati's CEO is Robert Koremans
  3. How much revenue does Recordati generate?

    Recordati generates $1.9B in revenue
  4. How much funding does Recordati have?

    Recordati has historically raised $0 in funding
  1. Where is Recordati's headquarters?

    Recordati's headquarters is in Milan Lombardy, IT
  2. How many employees does Recordati have?

    Recordati has 4,362 employees
  3. What sector does Recordati operate in?

    Recordati is in Pharmaceuticals
  4. Who are Recordati's competitors?

    Recordati's top competitors are Genentech, Shire, Ipsen

Trending Companies